allosteric GSK-3b inhibitors (Broad Institute)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nameallosteric GSK-3b inhibitors (Broad Institute)
Drug Alias Nameallosteric glycogen synthase kinase-3 beta inhibitors (Broad Institute)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 beta inhibitors
TargetsGlycogen synthase kinase-3 beta
Therapy Area/IndicationsBipolar DisorderDiabetes Mellitus, Type 2Cardiomegaly +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBroad Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBroad Institute
Active IndicationsN/A
Inactive IndicationsBipolar DisorderDiabetes Mellitus, Type 2Cardiomegaly +[5] 

Other Information

ATC CodeN/A
Related LinksN/A